UY37973A - Derivados de indol macrocíclicos - Google Patents

Derivados de indol macrocíclicos

Info

Publication number
UY37973A
UY37973A UY0001037973A UY37973A UY37973A UY 37973 A UY37973 A UY 37973A UY 0001037973 A UY0001037973 A UY 0001037973A UY 37973 A UY37973 A UY 37973A UY 37973 A UY37973 A UY 37973A
Authority
UY
Uruguay
Prior art keywords
compounds
macrocyclic
preparing
pharmaceutical compositions
indol derivatives
Prior art date
Application number
UY0001037973A
Other languages
English (en)
Inventor
Philipp Buchgraber Dr
Kai Thede Dr
Anne Mengel Dr
Clara Christ Dr
Joachim Kuhnke Dr
Sarah Anna Liesa Johannes Dr
Ulrich Klar Dr
Ulrike Sack Dr
Stefan Kaulfuss Dr
Nicolas Werbeck Dr
Ursula Mönning Dr
Katrin Nowak-Reppel Dr
Mark Fitzgerald
Christopher Nasveschuk
Kiel Lazarski
Laura Furst
Chris Lemke
David Mckinney
James Ferrara Steven
Guo Wei
Ryan Mccarren Patrick
H Serrano-Wu Michael
Amaury Ernesto Fernandez-Montalvan Dr
Original Assignee
Bayer Ag
Bayer Pharma AG
Broad Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG, Broad Inst Inc filed Critical Bayer Ag
Publication of UY37973A publication Critical patent/UY37973A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a derivados macrocíclicos de indol de la fórmula general (I): en donde R1, R2, R3, R4, R5, R6, A y L son como se definen en la presente, métodos de preparación de dichos compuestos, compuestos intermediarios útiles para preparar dichos compuestos, composiciones farmacéuticas y combinaciones que comprenden dichos compuestos y el uso de dichos compuestos para producir composiciones farmacéuticas para el tratamiento o profilaxis de enfermedades, en particular de trastornos hiperproliferativos, como un único agente o en combinación con otros ingredientes activos.
UY0001037973A 2017-11-17 2018-11-15 Derivados de indol macrocíclicos UY37973A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762588055P 2017-11-17 2017-11-17

Publications (1)

Publication Number Publication Date
UY37973A true UY37973A (es) 2019-06-28

Family

ID=64500338

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037973A UY37973A (es) 2017-11-17 2018-11-15 Derivados de indol macrocíclicos

Country Status (6)

Country Link
US (1) US11401278B2 (es)
EP (1) EP3710456B1 (es)
AR (1) AR113886A1 (es)
TW (1) TW201932473A (es)
UY (1) UY37973A (es)
WO (1) WO2019096911A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10981932B2 (en) 2016-05-19 2021-04-20 Bayer Aktiengesellschaft Macrocyclic indole derivatives
EP3710456B1 (en) 2017-11-17 2022-09-21 The Broad Institute, Inc. Macrocyclic indole derivatives
EP3710451A1 (en) 2017-11-17 2020-09-23 Bayer Aktiengesellschaft Substituted macrocyclic indole derivatives
US11286263B2 (en) 2017-11-17 2022-03-29 The Broad Institute, Inc. Macrocyclic fluorine substituted indole derivatives
EP3710450A1 (en) 2017-11-17 2020-09-23 Bayer Aktiengesellschaft Macrocyclic chlorine substituted indole derivatives
WO2019096905A1 (en) 2017-11-17 2019-05-23 Bayer Aktiengesellschaft Macrocyclic chlorine substituted indole derivatives

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008242983B2 (en) 2007-04-16 2013-07-11 Abbvie Inc. 7-substituted indole Mcl-1 inhibitors
JP5496876B2 (ja) 2007-04-16 2014-05-21 アッヴィ・インコーポレイテッド ７−置換されていないインドール系Ｍｃｌ−１阻害薬
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
US10093640B2 (en) 2012-09-21 2018-10-09 Vanderbilt University Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors
WO2015031608A1 (en) 2013-08-28 2015-03-05 Vanderbilt University Substituted indole mcl-1 inhibitors
US10533010B2 (en) 2014-03-27 2020-01-14 Vanderbilt University Substituted indole Mcl-1 inhibitors
US9949965B2 (en) 2014-10-17 2018-04-24 Vanderbilt University Tricyclic indole Mcl-1 inhibitors and uses thereof
AU2017228385B2 (en) 2016-03-04 2021-11-04 Vanderbilt University Substituted indole Mcl-1 inhibitors
CR20180499A (es) 2016-04-22 2019-01-25 Astrazeneca Ab Inhibidores de mcl1 macrocicliclos para tratar el cancer
US10981932B2 (en) 2016-05-19 2021-04-20 Bayer Aktiengesellschaft Macrocyclic indole derivatives
WO2017198341A1 (en) 2016-05-19 2017-11-23 Bayer Aktiengesellschaft Macrocyclic indole derivatives
WO2018098534A1 (en) 2016-12-02 2018-06-07 Garvan Institute Of Medical Research Methods of treating cancer and reagents thereof
EP3710450A1 (en) 2017-11-17 2020-09-23 Bayer Aktiengesellschaft Macrocyclic chlorine substituted indole derivatives
WO2019096905A1 (en) 2017-11-17 2019-05-23 Bayer Aktiengesellschaft Macrocyclic chlorine substituted indole derivatives
US11286263B2 (en) 2017-11-17 2022-03-29 The Broad Institute, Inc. Macrocyclic fluorine substituted indole derivatives
EP3710456B1 (en) 2017-11-17 2022-09-21 The Broad Institute, Inc. Macrocyclic indole derivatives
EP3710451A1 (en) 2017-11-17 2020-09-23 Bayer Aktiengesellschaft Substituted macrocyclic indole derivatives
WO2019096907A1 (en) 2017-11-17 2019-05-23 Bayer Aktiengesellschaft Aryl annulated macrocyclic indole derivatives
WO2020151738A1 (en) 2019-01-23 2020-07-30 Ascentage Pharma (Suzhou) Co., Ltd. Macrocyclic fused pyrrazoles as mcl-1 inhibitors
WO2020236556A1 (en) 2019-05-17 2020-11-26 The Broad Institute, Inc. Methods of preparing macrocyclic indoles

Also Published As

Publication number Publication date
US20210292341A1 (en) 2021-09-23
EP3710456A1 (en) 2020-09-23
AR113886A1 (es) 2020-06-24
EP3710456B1 (en) 2022-09-21
US11401278B2 (en) 2022-08-02
WO2019096911A1 (en) 2019-05-23
TW201932473A (zh) 2019-08-16

Similar Documents

Publication Publication Date Title
CO2019004137A2 (es) 1,2,4–triazolonas 2,4,5–trisustituidas
CL2018002920A1 (es) Nuevos derivados de pirazolopirimidina
DOP2019000117A (es) Nuevos derivados de quinolina
UY37250A (es) Derivados macrocíclicos de indol
CO2020001244A2 (es) Derivados de quinolina para tratar infecciones con helmintos
NI201900085A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
UY37973A (es) Derivados de indol macrocíclicos
UY37971A (es) Derivados de indol macrocíclicos sustituidos
UY37972A (es) Derivados de indol macrocíclicos sustituidos con cloro
UY37460A (es) 1,2,4-triazolonas con anelación en 4 y 5
DOP2016000208A (es) Benzimidazol-2-aminas como inhibidores de midh1
PH12017502001A1 (en) Amido-substituted cyclohexane derivatives
PH12020500134A1 (en) Dihydrooxadiazinones
UY37789A (es) Nuevos derivados de azaquinolina
UY37705A (es) Nuevos derivados de pirazol bicíclicos
CR20160433A (es) Nuevos compuestos
EA201791363A1 (ru) Пиразолопиридинамины в качестве ингибиторов mknk1 и mknk2
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
UY37444A (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y su uso
UY37032A (es) Compuestos de heteroarilbenzimidazol

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20231114